Ma, Changfeng, Shen, Jianfeng, and Zhang, Huiping (2025) Health Risk and Stock Return: Evidence From SARS and COVID-19. International Review of Financial Analysis, 25 (4). e70049.

PDF (Published Version) - Published Version Restricted to Repository staff only

Abstract

This study proposes a simple and practical approach to measure firm-level health risk by examining stock performance during a prior crisis of a similar type. Using Chinese A-share firms—the only major market significantly affected by both SARS and COVID-19—we show that SARS returns robustly predict COVID-19 returns, even after controlling for systematic risk, firm characteristics, survivorship, industry effects, and investor behavior. Further analysis indicates that both expected cash flow and discount rate channels contribute to such return predictability. By offering an easily implementable measure of health risk and providing out-of-sample evidence from a major non-U.S. market, our study highlights the persistent role of health risk in firm valuation and extends the literature on pandemic-related financial risk.

Item ID:	90466
Item Type:	Article (Research - C1)
ISSN:	1873-8079
Keywords:	COVID-19; health risk exposure; SARS
Copyright Information:	© 2025 International Review of Finance Ltd
Date Deposited:	11 Feb 2026 00:56
FoR Codes:	38 ECONOMICS > 3801 Applied economics > 380107 Financial economics @ 100%
SEO Codes:	11 COMMERCIAL SERVICES AND TOURISM > 1102 Financial services > 110202 Investment services (excl. superannuation) @ 100%
	More Statistics